JP2015091902A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015091902A5 JP2015091902A5 JP2015031316A JP2015031316A JP2015091902A5 JP 2015091902 A5 JP2015091902 A5 JP 2015091902A5 JP 2015031316 A JP2015031316 A JP 2015031316A JP 2015031316 A JP2015031316 A JP 2015031316A JP 2015091902 A5 JP2015091902 A5 JP 2015091902A5
- Authority
- JP
- Japan
- Prior art keywords
- factor viii
- viii composition
- liquid
- optionally
- reconstituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 84
- 229960000301 Factor VIII Drugs 0.000 claims 82
- 102000001690 Factor VIII Human genes 0.000 claims 82
- 108010054218 Factor VIII Proteins 0.000 claims 82
- 239000007788 liquid Substances 0.000 claims 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 12
- 239000003085 diluting agent Substances 0.000 claims 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 9
- 239000003381 stabilizer Substances 0.000 claims 7
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 claims 6
- RWSXRVCMGQZWBV-WDSKDSINSA-N Glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 6
- 229960003180 Glutathione Drugs 0.000 claims 6
- 108010024636 Glutathione Proteins 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-LIZSDCNHSA-N Trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 6
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 6
- 159000000007 calcium salts Chemical class 0.000 claims 6
- 239000000945 filler Substances 0.000 claims 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 6
- 239000000594 mannitol Substances 0.000 claims 6
- 235000010355 mannitol Nutrition 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 239000004094 surface-active agent Substances 0.000 claims 6
- 102100001249 ALB Human genes 0.000 claims 3
- 101710027066 ALB Proteins 0.000 claims 3
- 239000004475 Arginine Substances 0.000 claims 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 3
- 239000004471 Glycine Substances 0.000 claims 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 229940068977 Polysorbate 20 Drugs 0.000 claims 3
- 229940068968 Polysorbate 80 Drugs 0.000 claims 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N Raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 3
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 claims 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 3
- 239000007983 Tris buffer Substances 0.000 claims 3
- 235000004279 alanine Nutrition 0.000 claims 3
- 229940050528 albumin Drugs 0.000 claims 3
- 230000003078 antioxidant Effects 0.000 claims 3
- 239000003963 antioxidant agent Substances 0.000 claims 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L cacl2 Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims 3
- 239000001110 calcium chloride Substances 0.000 claims 3
- 229910001628 calcium chloride Inorganic materials 0.000 claims 3
- 229920001983 poloxamer Polymers 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 239000005720 sucrose Substances 0.000 claims 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 3
- 238000009472 formulation Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000010790 dilution Methods 0.000 claims 1
Claims (33)
- 患者を処置するときに使用する第VIII因子組成物であって、
前記凍結乾燥第VIII因子組成物は、アルブミンを添加することなく処方されたある体積の液体第VIII因子組成物を凍結乾燥することにより入手可能であり、前記液体第VIII因子組成物は、第VIII因子に加えて、以下の処方賦形剤:
マンニトール、グリシン、およびアラニンからなる群より選択される4%から10%の充填剤;
スクロース、トレハロース、ラフィノース、およびアルギニンからなる群より選択される1%から4%の安定化剤;
1mMから5mMのカルシウム塩;
100mMから300mMのNaCl;および
およそ6と8の間のpHを維持するための緩衝剤
を含み、
前記稀釈液の体積は、液体第VIII因子組成物の体積に等しいかまたはそれより大きく、そして、
凍結乾燥第VIII因子組成物は、ある体積の稀釈液中で再構成されて、再構成第VIII因子組成物を調製することおよび前記再構成第VIII因子組成物が前記患者に投与されることを特徴とする、
使用する第VIII因子組成物。 - 再構成第VIII因子組成物を調製する方法であって、前記方法は、
(i)凍結乾燥第VIII因子組成物を提供する工程であって、前記凍結乾燥第VIII因子組成物は、前記組成物にアルブミンを添加することなく処方されたある体積の液体第VIII因子組成物を凍結乾燥することにより入手可能であり、前記液体第VIII因子組成物は、第VIII因子に加えて、以下の処方賦形剤:
マンニトール、グリシン、およびアラニンからなる群より選択される4%から10%の充填剤;
スクロース、トレハロース、ラフィノース、およびアルギニンからなる群より選択される1%から4%の安定化剤;
1mMから5mMのカルシウム塩;
100mMから300mMのNaCl;および
およそ6と8の間のpHを維持するための緩衝剤
を含む、工程と、
(ii)前記凍結乾燥第VIII因子組成物を、ある体積の稀釈液中で再構成する工程であって、前記稀釈液の体積は、前記液体第VIII因子組成物の体積に等しいかまたはそれより大きい、工程
とを包含する方法。 - 再構成第VIII因子組成物であって、前記再構成第VIII因子組成物は、
(i)凍結乾燥第VIII因子組成物であって、前記組成物は、アルブミンを添加することなく処方されたある体積の液体第VIII因子組成物を凍結乾燥することにより入手可能であり、前記液体第VIII因子組成物は、第VIII因子に加えて、以下の処方賦形剤:
マンニトール、グリシン、およびアラニンからなる群より選択される4%から10%の充填剤;
スクロース、トレハロース、ラフィノース、およびアルギニンからなる群より選択される1%から4%の安定化剤;
1mMから5mMのカルシウム塩;
100mMから300mMのNaCl;および
およそ6と8の間のpHを維持するための緩衝剤
を含む、凍結乾燥第VIII因子組成物と
(ii)前記液体第VIII因子組成物の体積に等しいかまたはそれより大きい、ある体積の稀釈液
とを含む、再構成第VIII因子組成物。 - 前記液体第VIII因子組成物の体積が2mLであり、前記稀釈剤の体積が2mLまたは5mLである、請求項1に記載の使用する第VIII因子組成物。
- 前記稀釈剤が水である、請求項1または4に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物が界面活性剤をさらに含み、前記界面活性剤がポリソルベート20、ポリソルベート80、Pluronic F68、およびBrij 35からなる群より任意選択的に選択され、任意選択的に約0.03%の量である、請求項1、4、または5に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記緩衝剤がTrisを、任意選択的に約20mMの量で含む、請求項1、4、5、または6に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記緩衝剤がヒスチジンを、任意選択的に約25mMの濃度で含む、請求項1、4、5、または6に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物が任意選択的に抗酸化剤を、任意選択的にグルタチオンを、任意選択的に0.05mg/mLと1.0mg/mLの間の量のグルタチオンをさらに含む、請求項1、4、5、6、7、または8に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記充填剤がマンニトールであり、任意選択的に約8%の量である、請求項1、4、5、6、7、8、または9に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記安定化剤がトレハロースであり、任意選択的に約2%の量である、請求項1、4、5、6、7、8、9、または10に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記NaClが200mMから250mMまでの量で、例えば、約225mMの量で存在する、請求項1、4、5、6、7、8、9、10、または11に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の前記カルシウム塩が塩化カルシウムである、請求項1、4、5、6、7、8、9、10、11、または12に記載の使用する第VIII因子組成物。
- 前記液体第VIII因子組成物の体積が2mLであり、前記稀釈剤の体積が2mLまたは5mLである、請求項2に記載の再構成第VIII因子組成物を調製する方法。
- 前記稀釈剤が水である、請求項2または14に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物がさらに界面活性剤を含み、前記界面活性剤は、ポリソルベート20、ポリソルベート80、Pluronic F68、およびBrij 35からなる群より任意選択的に選択され、任意選択的に約0.03%の量である、請求項2、14、または15に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の前記緩衝剤がTrisを、任意選択的に約20mMの量で含む、請求項2、14、15、または16に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の前記緩衝剤がヒスチジンを、任意選択的に約25mMの濃度で含む、請求項2、14、15、または16に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物が任意選択的に抗酸化剤を、任意選択的にグルタチオンを、任意選択的に0.05mg/mLと1.0mg/mLの間の量でグルタチオンをさらに含む、請求項2、14、15、16、17、または18に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の充填材がマンニトールであり、任意選択的に約8%の量である、請求項2、14、15、16、17、18、または19に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の前記安定化剤がトレハロースであり、任意選択的に約2%の量である、請求項2、14、15、16、17、18、19、または20に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の前記NaClが200mMから250mMまでの量で、例えば、約225mMの量で存在する、請求項2、14、15、16、17、18、19、20、または21に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の前記カルシウム塩が塩化カルシウムである、請求項2、14、15、16、17、18、19、20、21、または22に記載の再構成第VIII因子組成物を調製する方法。
- 前記液体第VIII因子組成物の体積が2mLであり、前記稀釈剤の体積が2mLまたは5mLである、請求項3に記載の再構成第VIII因子組成物。
- 前記稀釈剤が水である、請求項3または24に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物がさらに界面活性剤を含み、前記界面活性剤は、ポリソルベート20、ポリソルベート80、Pluronic F68、およびBrij 35からなる群より任意選択的に選択され、任意選択的に約0.03%の量である、請求項3、24、および25のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記緩衝剤がTrisを、任意選択的に約20mMの量で含む、請求項3および24〜26のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記緩衝剤がヒスチジンを、任意選択的に約25mMの濃度で含む、請求項3および24〜26のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物が任意選択的に抗酸化剤を、任意選択的にグルタチオンを、任意選択的に0.05mg/mLと1.0mg/mLの間の量でグルタチオンをさらに含む、請求項3および24〜28のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記充填材がマンニトールであり、任意選択的に約8%の量である、請求項3および24〜29のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記安定化剤がトレハロースであり、任意選択的に約2%の量である、請求項3および24〜30のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記NaClが200mMから250mMまでの量で、例えば、約225mMの量で存在する、請求項3および24〜31のいずれか一項に記載の再構成第VIII因子組成物。
- 前記液体第VIII因子組成物の前記カルシウム塩が塩化カルシウムである、請求項3および24〜32のいずれか一項に記載の再構成第VIII因子組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25527999A | 1999-02-22 | 1999-02-22 | |
US09/255,279 | 1999-02-22 | ||
US45275299A | 1999-12-01 | 1999-12-01 | |
US09/452,752 | 1999-12-01 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013227977A Division JP6038003B2 (ja) | 1999-02-22 | 2013-11-01 | アルブミンを含有していない新規の第viii因子処方物 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015220875A Division JP6253627B2 (ja) | 1999-02-22 | 2015-11-11 | アルブミンを含有していない新規の第viii因子処方物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015091902A JP2015091902A (ja) | 2015-05-14 |
JP2015091902A5 true JP2015091902A5 (ja) | 2016-01-07 |
JP6155442B2 JP6155442B2 (ja) | 2017-07-05 |
Family
ID=26944588
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000599425A Expired - Lifetime JP5149470B2 (ja) | 1999-02-22 | 2000-02-22 | 新規のアルブミンを含有していない第viii因子処方物 |
JP2008120035A Expired - Lifetime JP5006832B2 (ja) | 1999-02-22 | 2008-05-01 | アルブミンを含有していない新規の第viii因子処方物 |
JP2008255510A Expired - Lifetime JP5140539B2 (ja) | 1999-02-22 | 2008-09-30 | アルブミンを含有していない新規の第viii因子処方物 |
JP2012009767A Expired - Lifetime JP5596064B2 (ja) | 1999-02-22 | 2012-01-20 | アルブミンを含有していない新規の第viii因子処方物 |
JP2013227977A Expired - Lifetime JP6038003B2 (ja) | 1999-02-22 | 2013-11-01 | アルブミンを含有していない新規の第viii因子処方物 |
JP2015031316A Expired - Lifetime JP6155442B2 (ja) | 1999-02-22 | 2015-02-20 | アルブミンを含有していない新規の第viii因子処方物 |
JP2015220875A Expired - Lifetime JP6253627B2 (ja) | 1999-02-22 | 2015-11-11 | アルブミンを含有していない新規の第viii因子処方物 |
JP2017088289A Withdrawn JP2017125076A (ja) | 1999-02-22 | 2017-04-27 | アルブミンを含有していない新規の第viii因子処方物 |
JP2018125917A Pending JP2018172413A (ja) | 1999-02-22 | 2018-07-02 | アルブミンを含有していない新規の第viii因子処方物 |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000599425A Expired - Lifetime JP5149470B2 (ja) | 1999-02-22 | 2000-02-22 | 新規のアルブミンを含有していない第viii因子処方物 |
JP2008120035A Expired - Lifetime JP5006832B2 (ja) | 1999-02-22 | 2008-05-01 | アルブミンを含有していない新規の第viii因子処方物 |
JP2008255510A Expired - Lifetime JP5140539B2 (ja) | 1999-02-22 | 2008-09-30 | アルブミンを含有していない新規の第viii因子処方物 |
JP2012009767A Expired - Lifetime JP5596064B2 (ja) | 1999-02-22 | 2012-01-20 | アルブミンを含有していない新規の第viii因子処方物 |
JP2013227977A Expired - Lifetime JP6038003B2 (ja) | 1999-02-22 | 2013-11-01 | アルブミンを含有していない新規の第viii因子処方物 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015220875A Expired - Lifetime JP6253627B2 (ja) | 1999-02-22 | 2015-11-11 | アルブミンを含有していない新規の第viii因子処方物 |
JP2017088289A Withdrawn JP2017125076A (ja) | 1999-02-22 | 2017-04-27 | アルブミンを含有していない新規の第viii因子処方物 |
JP2018125917A Pending JP2018172413A (ja) | 1999-02-22 | 2018-07-02 | アルブミンを含有していない新規の第viii因子処方物 |
Country Status (19)
Country | Link |
---|---|
US (8) | US6586573B1 (ja) |
EP (5) | EP1154796B1 (ja) |
JP (9) | JP5149470B2 (ja) |
CN (3) | CN101683522B (ja) |
AT (1) | ATE365052T1 (ja) |
AU (1) | AU777972B2 (ja) |
BR (1) | BR0008405B1 (ja) |
CA (4) | CA2634674A1 (ja) |
CY (2) | CY1108030T1 (ja) |
CZ (3) | CZ307715B6 (ja) |
DE (1) | DE60035260T2 (ja) |
DK (4) | DK1154796T3 (ja) |
ES (4) | ES2541470T3 (ja) |
HK (4) | HK1106705A1 (ja) |
MX (1) | MXPA01008515A (ja) |
PL (4) | PL198123B1 (ja) |
PT (4) | PT2130554E (ja) |
RU (1) | RU2244556C2 (ja) |
WO (1) | WO2000048635A1 (ja) |
Families Citing this family (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7244824B2 (en) * | 1995-01-19 | 2007-07-17 | Quadrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
US7253262B2 (en) * | 1995-01-19 | 2007-08-07 | Quandrant Drug Delivery Limited | Dried blood factor composition comprising trehalose |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
US6214054B1 (en) | 1998-09-21 | 2001-04-10 | Edwards Lifesciences Corporation | Method for fixation of biological tissues having mitigated propensity for post-implantation calcification and thrombosis and bioprosthetic devices prepared thereby |
JP5149470B2 (ja) * | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第viii因子処方物 |
US6830917B2 (en) * | 2001-12-10 | 2004-12-14 | Baxter Healthcare S.A. | Method of isolation and purification of trypsin from pronase protease and use thereof |
EP1458408B1 (en) * | 2001-12-21 | 2009-04-15 | Novo Nordisk Health Care AG | Liquid composition of factor vii polypeptides |
KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
US6878168B2 (en) | 2002-01-03 | 2005-04-12 | Edwards Lifesciences Corporation | Treatment of bioprosthetic tissues to mitigate post implantation calcification |
US6982080B2 (en) * | 2002-03-15 | 2006-01-03 | Wyeth | Hydroxyethyl starch—containing polypeptide compositions |
GB0207092D0 (en) * | 2002-03-26 | 2002-05-08 | Sod Conseils Rech Applic | Stable pharmaceutical composition containing factor VIII |
US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
CN101912601B (zh) * | 2002-06-21 | 2012-08-29 | 诺和诺德医疗保健公司 | 因子vii多肽的稳定化固体组合物 |
GB0304636D0 (en) * | 2003-02-28 | 2003-04-02 | Britannia Pharmaceuticals Ltd | Pharmaceutical composition for nasal delivery |
EP1605968A2 (en) * | 2003-03-18 | 2005-12-21 | Novo Nordisk Health Care AG | Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides |
US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
WO2004103398A1 (en) * | 2003-05-23 | 2004-12-02 | Novo Nordisk Health Care Ag | Protein stabilization in solution |
JP4658041B2 (ja) * | 2003-06-25 | 2011-03-23 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Vii因子ポリペプチドの液体組成物 |
ATE446768T1 (de) * | 2003-07-01 | 2009-11-15 | Novo Nordisk Healthcare Ag | Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden |
DE10333317A1 (de) * | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
MXPA06001283A (es) * | 2003-08-05 | 2006-04-11 | Novo Nordisk As | Derivados de insulina novedosos. |
KR100560697B1 (ko) * | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
KR20120104619A (ko) * | 2003-08-14 | 2012-09-21 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 인자 vii 폴리펩티드의 액상 수성 약학적 조성물 |
EP1670507A4 (en) * | 2003-09-12 | 2007-10-17 | Antigenics Inc | VACCINE FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY HERPES SIMPLEX VIRUS |
EP2311437A1 (en) * | 2003-12-19 | 2011-04-20 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
GB0404586D0 (en) * | 2004-03-01 | 2004-04-07 | Britannia Pharmaceuticals Ltd | Improvements in or relating to organic materials |
AU2005225000A1 (en) * | 2004-03-04 | 2005-09-29 | Wyeth | Lyophilization method to improve excipient crystallization |
ES2357132T3 (es) * | 2004-03-19 | 2011-04-19 | Baxter International Inc. | Factor ixa para el tratamiento de trastornos hemorrágicos. |
US7319032B2 (en) * | 2004-04-22 | 2008-01-15 | Medtox | Non-sugar sweeteners for use in test devices |
KR100624013B1 (ko) * | 2004-06-25 | 2006-09-19 | 주식회사 녹십자홀딩스 | 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제 |
PT1835938E (pt) | 2004-12-27 | 2013-11-06 | Baxter Int | Conjugados de polímero-factor de von willebrand |
FR2881139A1 (fr) * | 2005-01-26 | 2006-07-28 | Agronomique Inst Nat Rech | Composition pour la lyophilisation de proteines |
WO2007014073A2 (en) * | 2005-07-22 | 2007-02-01 | Amgen Inc. | Concentrated protein lyophilates, methods, and uses |
KR20110128957A (ko) | 2005-11-01 | 2011-11-30 | 와이어쓰 엘엘씨 | 약물 재구성 또는 희석을 위한 염화나트륨 용액 |
DE602006017421D1 (de) * | 2005-11-09 | 2010-11-18 | Ajinomoto Kk | Screening-verfahren für kokumi-vermittelnde agentien |
WO2007055388A2 (en) | 2005-11-09 | 2007-05-18 | Ajinomoto Co., Inc. | Calcium receptor activator |
US8420144B2 (en) * | 2005-11-09 | 2013-04-16 | Ajinomoto Co., Inc. | Kokumi-imparting agent, method of using, and compositions containing same |
WO2007062040A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
WO2007074133A2 (en) | 2005-12-28 | 2007-07-05 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
US7985839B2 (en) | 2006-03-31 | 2011-07-26 | Baxter International Inc. | Factor VIII polymer conjugates |
US7982010B2 (en) | 2006-03-31 | 2011-07-19 | Baxter International Inc. | Factor VIII polymer conjugates |
US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
AU2007245190B2 (en) * | 2006-03-31 | 2011-07-21 | Takeda Pharmaceutical Company Limited | Pegylated factor VIII |
WO2007139553A1 (en) * | 2006-05-31 | 2007-12-06 | Genzyme Corporation | Use of polysaccharides for promotion of enzymatic activity |
CA2666485C (en) | 2006-10-27 | 2015-10-06 | Edwards Lifesciences Corporation | Biological tissue for surgical implantation |
EP2535058A3 (en) * | 2006-11-07 | 2013-04-10 | Sanofi Pasteur Biologics, LLC | Stabilization of vaccines by lyophilization |
ES2521490T3 (es) | 2006-12-15 | 2014-11-12 | Baxter International Inc. | Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada. |
FR2913020B1 (fr) | 2007-02-23 | 2012-11-23 | Biomethodes | Nouveaux facteurs viii pour le traitement des hemophiles de type a |
ES2365832T3 (es) * | 2007-03-05 | 2011-10-11 | Cadila Healthcare Limited | Composiciones que comprenden conjugados de peg-interferón alfa y rafinosa como crioprotector. |
AU2013204652B2 (en) * | 2007-04-26 | 2015-06-18 | Bayer Healthcare Llc | Stabilization of liquid solutions of recombinant protein for frozen storage |
RU2469739C2 (ru) | 2007-04-26 | 2012-12-20 | БАЙЕР ХЕЛСКЕА ЛЛСи | Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии |
MY151068A (en) * | 2007-05-08 | 2014-03-31 | Ajinomoto Kk | Low- fat food |
US9101691B2 (en) | 2007-06-11 | 2015-08-11 | Edwards Lifesciences Corporation | Methods for pre-stressing and capping bioprosthetic tissue |
ES2744384T3 (es) * | 2007-06-13 | 2020-02-24 | Novo Nordisk As | Formulación farmacéutica que comprende un derivado de insulina |
GB0715285D0 (en) * | 2007-08-06 | 2007-09-12 | Britannia Pharmaceuticals Ltd | Improvements in or relating to powdered medicaments for nasal delivery |
CN101376022B (zh) * | 2007-08-31 | 2011-11-30 | 上海医药工业研究院 | 含聚乙二醇降纤酶的药物组合物 |
US8357387B2 (en) | 2007-12-21 | 2013-01-22 | Edwards Lifesciences Corporation | Capping bioprosthetic tissue to reduce calcification |
US20100316625A1 (en) * | 2007-12-21 | 2010-12-16 | Inspiration Biopharmaceuticals, Inc. | Stabilized factor ix formulations containing trehalose |
JP5727790B2 (ja) | 2007-12-27 | 2015-06-03 | バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated | 細胞培養プロセス |
EP2113564A1 (en) * | 2008-05-01 | 2009-11-04 | Arecor Limited | Protein formulation |
US9884019B2 (en) * | 2008-08-05 | 2018-02-06 | Wyeth Llc | Lyophilization above collapse |
KR101921698B1 (ko) | 2008-08-21 | 2018-11-26 | 옥타파마 아게 | 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ |
MX2011002159A (es) * | 2008-08-27 | 2011-03-29 | Schering Corp | Formulaciones liofilizadas de anticuerpos anti-interleucina-23p19 construidos por ingenieria. |
PT2337580E (pt) * | 2008-09-03 | 2012-05-28 | Octapharma Ag | Composições estabilizadas para o factor viii produzido de forma recombinante |
CA2734275A1 (en) * | 2008-09-10 | 2010-03-18 | Genentech, Inc. | Compositions and methods for the prevention of oxidative degradation of proteins |
AU2009309623B9 (en) * | 2008-10-30 | 2014-10-02 | Novo Nordisk A/S | Treating diabetes melitus using insulin injections with less than daily injection frequency |
CA2742328C (en) | 2008-11-07 | 2019-02-26 | Baxter International Inc. | Factor viii formulations |
EP2248518B1 (en) | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
EP3093029A1 (en) | 2009-07-27 | 2016-11-16 | Baxalta GmbH | Blood coagulation protein conjugates |
WO2011017055A2 (en) | 2009-07-27 | 2011-02-10 | Baxter International Inc. | Blood coagulation protein conjugates |
ES2590679T3 (es) | 2009-07-27 | 2016-11-23 | Lipoxen Technologies Limited | Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre |
US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
GB0915480D0 (en) * | 2009-09-04 | 2009-10-07 | Arecor Ltd | Stable formulation of factor viii |
KR20210054598A (ko) | 2009-09-21 | 2021-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 안정화된 액체 및 동결건조된 adamts13 제제 |
JP2013510158A (ja) | 2009-11-03 | 2013-03-21 | グリフオルス・セラピユーテイクス・インコーポレーテツド | α‐1プロテイナーゼインヒビターのための組成物、方法およびキット |
BR112012012460B1 (pt) | 2009-11-24 | 2020-06-23 | Grifols Therapeutics Inc. | Método de liofilização de uma composição |
MX2012008453A (es) * | 2010-01-19 | 2012-11-21 | Hanmi Science Co Ltd | Formulaciones liquiddas para un conjugado de eritropoientina de accion prolongada. |
BR112012023769B1 (pt) | 2010-03-23 | 2020-11-10 | Edwards Lifesciences Corporation | método para preparar material de membrana de tecido bioprotético |
US8906601B2 (en) | 2010-06-17 | 2014-12-09 | Edwardss Lifesciences Corporation | Methods for stabilizing a bioprosthetic tissue by chemical modification of antigenic carbohydrates |
AU2011301803A1 (en) * | 2010-09-17 | 2013-03-21 | Baxalta GmbH | Stabilization of immunoglobulins and other proteins through aqueous formulations with sodium chloride at weak acidic to neutral pH |
ES2639617T3 (es) * | 2010-10-12 | 2017-10-27 | Merz Pharma Gmbh & Co. Kgaa | Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos |
RU2013123515A (ru) | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
MY165089A (en) | 2010-11-05 | 2018-02-28 | Baxalta Inc | A new variant of antihemophilic factor viii having increased specific activity |
US9351829B2 (en) | 2010-11-17 | 2016-05-31 | Edwards Lifesciences Corporation | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
EP2651433A1 (en) * | 2010-12-16 | 2013-10-23 | Novo Nordisk A/S | Aqueous factor viii solution |
MX345608B (es) | 2010-12-22 | 2017-02-07 | Baxalta Inc | Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina. |
BRPI1105317A2 (pt) | 2011-01-24 | 2013-04-30 | Fundacco Hemoct De Ribeirco Preto | produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1 |
KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
CN103703141B (zh) | 2011-04-08 | 2016-08-17 | 伯乐实验室公司 | 具有降低的非特异性活性的pcr反应混合物 |
US8697410B2 (en) | 2011-04-08 | 2014-04-15 | Bio-Rad Laboratories, Inc. | SSO7-polymerase conjugates with decreased non-specific activity |
WO2014031718A1 (en) | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
US10238771B2 (en) | 2012-11-08 | 2019-03-26 | Edwards Lifesciences Corporation | Methods for treating bioprosthetic tissue using a nucleophile/electrophile in a catalytic system |
CN105209487A (zh) * | 2013-03-15 | 2015-12-30 | 拜耳医药保健有限公司 | 重组因子viii制剂 |
EA201890671A1 (ru) * | 2013-03-15 | 2019-01-31 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора viii |
US9839579B2 (en) | 2013-04-24 | 2017-12-12 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
US9700486B2 (en) | 2013-04-24 | 2017-07-11 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
JP2016519127A (ja) | 2013-04-30 | 2016-06-30 | ノヴォ ノルディスク アー/エス | 新規投与レジメン |
KR102058864B1 (ko) * | 2013-12-16 | 2019-12-24 | 주식회사 티움바이오 | 인자 vii의 융합 단백질을 포함하는 안정성이 개선된 약학적 조성물 |
AU2015240354A1 (en) | 2014-04-01 | 2016-11-17 | Advantech Bioscience Farmaceutica Ltda. | Stabilization of Factor VIII without calcium as an excipient |
WO2015149143A2 (en) * | 2014-04-01 | 2015-10-08 | Advantech Bioscience Farmacêutica Ltda. | Stable factor viii formulations with low sugar-glycine |
MX2017000862A (es) * | 2014-08-04 | 2017-05-01 | Csl Ltd | Formulacion de factor viii. |
CN107073082B (zh) * | 2014-08-20 | 2021-04-30 | 博尔托拉制药公司 | Xa因子解毒剂的冻干制剂 |
SG11201702757YA (en) * | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
WO2016169453A1 (zh) | 2015-04-21 | 2016-10-27 | 舒泰神(北京)生物制药股份有限公司 | 神经生长因子组合物及注射粉剂 |
CN107660149B (zh) | 2015-04-21 | 2021-04-27 | 舒泰神(北京)生物制药股份有限公司 | 一种神经生长因子组合物及注射粉剂 |
EP3319930A4 (en) * | 2015-07-07 | 2019-04-10 | NanoBio Corporation | METHOD AND COMPOSITIONS FOR STABILIZING PROTEINS |
GB2556002B (en) | 2015-07-07 | 2020-12-16 | Bluewillow Biologics Inc | Methods and compositions for nanoemulsion vaccine formulations |
US10287338B2 (en) | 2015-07-10 | 2019-05-14 | Miran NERSISSIAN | Factor VIII protein compositions and methods of treating of hemophilia A |
EP3167877A1 (en) * | 2015-11-12 | 2017-05-17 | Bayer Pharma Aktiengesellschaft | Method for the production of freeze-dried pellets comprising factor viii |
ES2884119T3 (es) * | 2016-02-24 | 2021-12-10 | Alexion Pharma Inc | Fórmulas liofilizadas para antídoto contra el factor Xa |
SI3463308T1 (sl) * | 2016-06-01 | 2022-04-29 | Servier IP UK Limited | Formulacije polialkilenoksidne asparaginaze in postopki za pripravo in uporabo le-teh |
CN110381962B (zh) * | 2016-12-21 | 2023-10-13 | 孙崇谨 | 用于血浆蛋白的活性保存的新颖方法 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JP6630315B2 (ja) | 2017-06-27 | 2020-01-15 | 矢崎総業株式会社 | ノイズ低減ユニット |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
CN113382714A (zh) * | 2019-01-06 | 2021-09-10 | 恩多全球美学有限公司 | 胶原酶制剂及其制备方法 |
WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
CN110772487B (zh) * | 2019-12-09 | 2021-09-21 | 湖南科伦制药有限公司 | 一种二乙酰氨乙酸乙二胺的冻干方法 |
CN112121009B (zh) * | 2020-09-24 | 2022-12-02 | 科兴生物制药股份有限公司 | 一种聚乙二醇修饰重组人粒细胞刺激因子新制剂 |
TW202227133A (zh) | 2020-09-24 | 2022-07-16 | 美商默沙東藥廠 | 計畫性死亡受體1(pd-1)抗體及玻尿酸酶變異體及其片段之穩定調配物及其使用方法 |
US20220380439A1 (en) | 2020-11-09 | 2022-12-01 | Takeda Pharmaceutical Company Limited | Purification of fviii from plasma using silicon oxide adsorption |
WO2022217041A1 (en) * | 2021-04-09 | 2022-10-13 | Hyalo Technologies, LLC | Method of sterilization of biologics |
CA3228445A1 (en) * | 2021-08-11 | 2023-02-16 | Salvador Grancha Gamon | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained |
CN114015758B (zh) * | 2021-10-15 | 2022-06-24 | 无锡百泰克生物技术有限公司 | 一种冻干保护剂、荧光pcr检测试剂盒及冻干工艺 |
Family Cites Families (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB941019A (en) | 1961-04-27 | 1963-11-06 | Crookes Lab Ltd | Improvements in and relating to the stability of anti-haemophilic globulin (factor viii) |
US3389314A (en) | 1962-05-07 | 1968-06-18 | Penn Controls | Proportional silicon controlled rectifier driven system for a heat motor |
US3681126A (en) | 1969-11-25 | 1972-08-01 | Monsanto Co | Flame retardant article containing tris-(3 - halo - 2-hydroxypropyl)-hydroxymethylphosphonium chloride |
US3770631A (en) | 1971-06-29 | 1973-11-06 | Baxter Laboratories Inc | Clarification of blood serum and plasma |
US3839314A (en) | 1971-06-29 | 1974-10-01 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4073886A (en) | 1973-01-30 | 1978-02-14 | Baxter Travenol Laboratories, Inc. | Blood fractionation process using block copolymers of ethylene oxide and polyoxypropylene |
US3980432A (en) | 1973-04-02 | 1976-09-14 | Behringwerke Aktiengesellschaft | Partial thromboplastin, its use as diagnostic agent and process for preparing it |
US3893990A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using a block copolymer of ethylene oxide and polyoxypropylene |
US3893991A (en) | 1973-04-05 | 1975-07-08 | Baxter Laboratories Inc | Clarification of blood serum and plasma using block copolymers of ethylene oxide and polyoxypropylene |
US4189425A (en) | 1975-04-11 | 1980-02-19 | Edward Shanbrom, Inc. | Method of preserving blood plasma I |
US4086218A (en) | 1975-04-11 | 1978-04-25 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
US4069216A (en) | 1975-06-16 | 1978-01-17 | Edward Shanbrom, Inc. | Simplified methods for preparation of very high purity Factor VIII concentrate |
US4089944A (en) | 1975-12-22 | 1978-05-16 | Baxter Travenol Laboratories, Inc. | Rapidly solubilized AHF composition and process for preparing same |
US4027013A (en) | 1976-01-22 | 1977-05-31 | William L. Wilson | Clottable fibrinogen free factor VIII and albumin product and process |
SU663404A1 (ru) | 1976-12-30 | 1979-05-25 | Московский Ордена Ленина И Ордена Трудового Красного Знамени Государственный Университет Им. М.В.Ломоносова | Способ получени фибрин-мономера |
US4137223A (en) | 1977-05-16 | 1979-01-30 | Edward Shanbrom, Inc. | Method of preserving blood plasma II |
SE443293B (sv) | 1978-01-25 | 1986-02-24 | Blombaeck E G B | Blodfraktionsframstellning |
DE2916711A1 (de) | 1979-04-25 | 1980-11-06 | Behringwerke Ag | Blutgerinnungsfaktoren und verfahren zu ihrer herstellung |
US4783441A (en) | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
FR2460305A2 (fr) | 1979-06-29 | 1981-01-23 | Merieux Inst | Procede de preparation d'un concentre de facteur viii |
US4386068A (en) | 1980-02-26 | 1983-05-31 | Cutter Laboratories, Inc. | Antihemophilic factor concentrate and method for preparation |
US4623717A (en) | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
DE3176491D1 (en) | 1980-03-05 | 1987-11-26 | Miles Lab | Pasteurized therapeutically active protein compositions |
US4440679A (en) | 1980-03-05 | 1984-04-03 | Cutter Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4341764A (en) | 1980-03-05 | 1982-07-27 | Cutter Laboratories, Inc. | Method of preparing fibronectin and antihemophilic factor |
JPS56127308A (en) | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
JPS56135418A (en) | 1980-03-27 | 1981-10-22 | Green Cross Corp:The | Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human |
AT369263B (de) | 1980-08-27 | 1982-12-27 | Immuno Ag | Verfahren zur herstellung eines faktor viii(ahf) -hochkonzentrates |
DE3033932C2 (de) | 1980-09-10 | 1984-05-24 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Verfahren zur Kaltsterilisation von Blutgerinnungsfaktor VIII enthaltenden Präparaten |
JPS5770814A (en) | 1980-10-17 | 1982-05-01 | Isamu Horikoshi | Oral preparation of blood clotting eighth factor |
US4495278A (en) | 1981-04-27 | 1985-01-22 | Baxter Travenol Laboratories, Inc. | Process for making novel blood clotting enzyme compositions |
US4382083A (en) | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4479938A (en) | 1981-06-25 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Therapeutic composition containing factor VIIa |
JPS5874617A (ja) | 1981-10-28 | 1983-05-06 | Green Cross Corp:The | 人由来血液凝固第7因子含有水溶液の加熱処理方法 |
US4456590B2 (en) | 1981-11-02 | 1989-05-30 | Heat treatment of lyphilized blood clotting factor viii concentrate | |
US4591505A (en) | 1982-04-14 | 1986-05-27 | New York Blood Center, Inc. | Process for inactivating hepatitis B virus |
US4481189A (en) | 1982-04-14 | 1984-11-06 | New York Blood Center Inc. | Process for preparing sterilized plasma and plasma derivatives |
US4495175A (en) | 1982-08-05 | 1985-01-22 | University Of Rochester | Preparation of highly purified human antihemophilic factor |
DE3230849A1 (de) | 1982-08-19 | 1984-02-23 | Behringwerke Ag, 3550 Marburg | Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung |
DE3237512A1 (de) | 1982-10-09 | 1984-04-12 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat |
GB2129685B (en) | 1982-11-11 | 1985-11-13 | Nat Biolog Standards Board | Anti-haemophilic compositions |
JPS59134730A (ja) | 1983-01-20 | 1984-08-02 | Green Cross Corp:The | 血液凝固第8因子の加熱処理法 |
WO1984003628A1 (en) | 1983-05-09 | 1984-09-27 | Nordisk Insulinlab | A concentrate of the antihemophilic factor viii and a process for producing it |
IE80858B1 (en) | 1983-03-31 | 1999-04-21 | Scripps Research Inst | New factor viii coagulant polypeptides |
US4727027A (en) | 1983-05-02 | 1988-02-23 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
US4748120A (en) | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
AT379510B (de) | 1983-05-20 | 1986-01-27 | Immuno Ag | Verfahren zur herstellung einer faktor viii (ahf) -haeltigen praeparation |
DE3318521A1 (de) | 1983-05-20 | 1984-11-22 | Lentia GmbH Chem. u. pharm. Erzeugnisse - Industriebedarf, 8000 München | Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats |
US4540573A (en) | 1983-07-14 | 1985-09-10 | New York Blood Center, Inc. | Undenatured virus-free biologically active protein derivatives |
DE3336631A1 (de) | 1983-10-08 | 1985-04-18 | Behringwerke Ag, 3550 Marburg | Verfahren zur pasteurisierung von plasma oder von konzentraten der blutgerinnungsfaktoren ii, vii, ix und x |
US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
US4693981A (en) | 1983-12-20 | 1987-09-15 | Advanced Genetics Research Institute | Preparation of inactivated viral vaccines |
JPS6122022A (ja) | 1983-12-28 | 1986-01-30 | Green Cross Corp:The | 血漿蛋白の加熱処理方法 |
EP0150735B2 (en) | 1984-01-12 | 2004-01-07 | Chiron Corporation | Protein composition exhibiting coagulation activity and method for the preparation thereof |
WO1987000196A1 (en) | 1985-07-09 | 1987-01-15 | Quadrant Bioresources Limited | Protection of proteins and the like |
AT389815B (de) | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
US4831012A (en) | 1984-03-23 | 1989-05-16 | Baxter International Inc. | Purified hemoglobin solutions and method for making same |
JPS60199829A (ja) | 1984-03-24 | 1985-10-09 | Nippon Sekijiyuujishiya | 高純度抗血友病グロブリンの製造方法 |
US5043428A (en) | 1984-08-31 | 1991-08-27 | Behringwerke Aktiengesellschaft | Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production |
US4543210A (en) | 1984-10-04 | 1985-09-24 | Miles Laboratories, Inc. | Process for producing a high purity antihemophilic factor concentrate |
US4613501A (en) | 1984-12-21 | 1986-09-23 | New York Blood Center, Inc. | Inactivation of viruses in labile blood derivatives |
JPS61271222A (ja) * | 1985-05-24 | 1986-12-01 | Dainippon Pharmaceut Co Ltd | ヒトインターロイキン1ポリペプチド及びその製造法 |
US4847362A (en) | 1985-02-01 | 1989-07-11 | New York University | Method for purifying antihemophilic factor |
US4952675A (en) | 1985-02-01 | 1990-08-28 | New York University | Method for purifying antihemophilic factor |
US4743680A (en) | 1985-02-01 | 1988-05-10 | New York University | Method for purifying antihemophilic factor |
AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
US4758657A (en) | 1985-07-11 | 1988-07-19 | Armour Pharmaceutical Company | Method of purifying Factor VIII:C |
EP0212040B1 (de) | 1985-08-05 | 1990-05-23 | IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte | Verfahren zur Herstellung von Präparationen auf Basis von Blutgerinnungsfaktoren |
AU6487286A (en) | 1985-11-08 | 1987-05-14 | Baxter Travenol Laboratories Inc. | Antihemophilic factor by cold precipitation |
US5180583A (en) | 1985-11-26 | 1993-01-19 | Hedner Ulla K E | Method for the treatment of bleeding disorders |
JPS62195331A (ja) | 1986-02-24 | 1987-08-28 | Nippon Sekijiyuujishiya | 血液凝固第8因子製剤の製法 |
AT390374B (de) | 1986-03-18 | 1990-04-25 | Schwab & Co Gmbh | Verfahren zum pasteurisieren von plasmaprotein und plasmaproteinfraktionen |
DE3609431A1 (de) | 1986-03-20 | 1987-09-24 | Biotest Pharma Gmbh | Verfahren zur herstellung eines den blutgerinnungsfaktor viii enthaltenden, sterilen praeparates |
US4841023A (en) | 1986-06-25 | 1989-06-20 | New York Blood Center, Inc. | Inactivation of viruses in labile protein-containing compositions using fatty acids |
AT391808B (de) | 1986-11-03 | 1990-12-10 | Immuno Ag | Verfahren zur herstellung einer faktor viii (ahf)-haeltigen fraktion |
GB8628104D0 (en) | 1986-11-25 | 1986-12-31 | Connaught Lab | Pasteurization of immunoglobin solutions |
CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
ES2006632A6 (es) | 1987-04-21 | 1989-05-01 | Green Cross Corp | Procedimiento de tratamiento termico de fibrinogeno. |
IL86417A (en) | 1987-05-22 | 1992-09-06 | Armour Pharma | Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers |
US4876241A (en) | 1987-05-22 | 1989-10-24 | Armour Pharmaceutical Company | Stabilization of biological and pharmaceutical products during thermal inactivation of viral and bacterial contaminants |
US4795806A (en) | 1987-07-16 | 1989-01-03 | Miles Laboratories, Inc. | Phospholipid affinity purification of Factor VIII:C |
JPH0387173A (ja) | 1987-09-10 | 1991-04-11 | Teijin Ltd | ヒト活性化天然型ファクター8cの製造方法及びそれに用いる形質転換体 |
DE3730533A1 (de) | 1987-09-11 | 1989-03-30 | Biotest Pharma Gmbh | Verfahren zur sterilisation von plasma oder plasmafraktionen |
KR890004724A (ko) * | 1987-09-17 | 1989-05-09 | 히사시 미하라 | 신규 프로테아제 제제(製劑) |
US5605884A (en) | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
CA1329760C (en) | 1987-10-29 | 1994-05-24 | Ted C. K. Lee | Plasma and recombinant protein formulations in high ionic strength media |
US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
US5177191A (en) | 1987-12-21 | 1993-01-05 | Miles, Inc. | Gel filtration of factor VIII |
DK18288D0 (da) | 1988-01-15 | 1988-01-15 | Nordisk Gentofte | Fremgangsmaade til pasteurisering af vandige oploesninger af faktor viii |
WO1989009784A1 (en) | 1988-04-08 | 1989-10-19 | Commonwealth Serum Laboratories Commission | Production of heat-stable factor viii concentrate |
US4981951A (en) | 1988-04-14 | 1991-01-01 | Miles Inc. | Lectin affinity chromatography of factor VIII |
FR2632309B1 (fr) | 1988-06-07 | 1990-08-24 | Lille Transfusion Sanguine | Procede de purification par voie chromatographique de proteines, notamment de facteur viii, et les produits obtenus |
US5047249A (en) | 1988-07-22 | 1991-09-10 | John Morris Co., Inc. | Compositions and methods for treating skin conditions and promoting wound healing |
US5051353A (en) | 1988-08-09 | 1991-09-24 | The United States Of America As Represented By The Secretary Of The Navy | Preservation and restoration of hemoglobin in blood substitutes |
JPH02157231A (ja) * | 1988-12-07 | 1990-06-18 | Bio Kagaku Kenkyusho:Kk | 細胞増殖抑制剤 |
DE3904354A1 (de) | 1989-02-14 | 1990-08-16 | Behringwerke Ag | Pasteurisiertes, gereinigtes von willebrand-faktor-konzentrat und verfahren zu seiner herstellung |
FR2665449B1 (fr) | 1990-08-02 | 1995-04-14 | Aquitaine Developp Transf Sang | Procede de fabrication de facteur von willebrand ayant une tres haute purete, depourvu en majeure partie de facteur antihemophilique (fviiic), et facteur von willebrand ainsi obtenu, ainsi qu'une composition pharmaceutique le contenant. |
US5760183A (en) | 1989-02-17 | 1998-06-02 | Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques | Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same |
CN1047342A (zh) | 1989-05-13 | 1990-11-28 | 杭州市中心血站 | 因子viii的生产及其病毒灭活方法 |
ES2042138T3 (es) | 1989-05-24 | 1993-12-01 | Miles Inc. | Filtracion en gel del factor viii tratado termicamente. |
GB8913183D0 (en) * | 1989-06-08 | 1989-07-26 | Central Blood Lab Authority | Chemical products |
US5138034A (en) | 1989-07-12 | 1992-08-11 | The Green Cross Corporation | Method of fractionating plasma proteins |
US5062498A (en) | 1989-07-18 | 1991-11-05 | Jaromir Tobias | Hydrostatic power transfer system with isolating accumulator |
EP0410207B1 (en) | 1989-07-24 | 1997-01-22 | Bayer Corporation | Stabilization of highly purified proteins |
DE3926034C3 (de) | 1989-08-07 | 1996-11-21 | Behringwerke Ag | Verfahren zur Herstellung eines stabilen Faktors VIII |
FR2651437A1 (fr) | 1989-09-05 | 1991-03-08 | Lille Transfusion Sanguine | Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total. |
DK162233C (da) | 1989-11-09 | 1992-03-16 | Novo Nordisk As | Fremgangsmaade til isolering af faktor viii fra blodplasma og pharmaceutisk praeparat indeholdende den saaledes isolerede fator viii |
SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
US5439882A (en) | 1989-12-29 | 1995-08-08 | Texas Tech University Health Sciences Center | Blood substitute |
DE4001451A1 (de) | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
US5798238A (en) | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
US5587490A (en) | 1990-04-16 | 1996-12-24 | Credit Managers Association Of California | Method of inactivation of viral and bacterial blood contaminants |
WO1991017194A1 (en) * | 1990-05-07 | 1991-11-14 | Exxon Chemical Patents Inc. | UNSATURATED α-OLEFIN COPOLYMERS AND METHOD FOR PREPARATION THEREOF |
US5378612A (en) | 1990-05-11 | 1995-01-03 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Culture medium for production of recombinant protein |
US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
US5712086A (en) | 1990-05-15 | 1998-01-27 | New York Blood Center, Inc. | Process for transfusing cell containing fractions sterilized with radiation and a quencher of type I and type II photodynamic reactions |
FR2662166A1 (fr) | 1990-05-18 | 1991-11-22 | Fondation Nale Transfusion San | Procede de preparation de facteur viii de tres haute purete comprenant une etape rapide d'immunoadsorption. |
IT1248723B (it) | 1990-06-12 | 1995-01-26 | Scalvo S P A | Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo |
WO1992001229A1 (en) | 1990-07-12 | 1992-01-23 | Baxter Diagnostics Inc. | FACTOR VIII:Ca CHROMOGENIC ASSAY |
CA2051092C (en) | 1990-09-12 | 2002-07-23 | Stephen A. Livesey | Method and apparatus for cryopreparation, dry stabilization and rehydration of biological suspensions |
US5272135A (en) | 1991-03-01 | 1993-12-21 | Chiron Ophthalmics, Inc. | Method for the stabilization of methionine-containing polypeptides |
FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
DE4111393A1 (de) | 1991-04-09 | 1992-10-15 | Behringwerke Ag | Stabilisierte faktor viii-praeparationen |
SE468480B (sv) | 1991-05-24 | 1993-01-25 | Arne Holmgren | Modifierat tioredoxin och dess anvaendning |
AU2309692A (en) | 1991-07-03 | 1993-02-11 | Cryolife, Inc. | Method for stabilization of biomaterials |
US5254350A (en) | 1991-07-22 | 1993-10-19 | Helena Laboratories Corporation | Method of preparing a thromboplastin extract |
CA2078721A1 (en) | 1991-09-24 | 1993-03-25 | Hiroshi Yonemura | Process for preparing human coagulation factor viii protein complex |
FR2681867B1 (fr) | 1991-09-26 | 1993-12-31 | Pasteur Merieux Serums Vaccins | Procede de purification du facteur viii et preparations obtenues. |
US5278289A (en) | 1991-11-12 | 1994-01-11 | Johnson Alan J | Antihemophilic factor stabilization |
US5192743A (en) | 1992-01-16 | 1993-03-09 | Genentech, Inc. | Reconstitutable lyophilized protein formulation |
JPH05331071A (ja) * | 1992-01-17 | 1993-12-14 | Asahi Chem Ind Co Ltd | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 |
AT399818B (de) | 1992-04-24 | 1995-07-25 | Immuno Ag | Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation |
US5288853A (en) | 1992-04-30 | 1994-02-22 | Alpha Therapeutic Corporation | Factor viii purification process |
US5399670A (en) | 1992-04-30 | 1995-03-21 | Alpha Therapeutic Corporation | Solubilization and stabilization of factor VIII complex |
US5378601A (en) | 1992-07-24 | 1995-01-03 | Montefiore Medical Center | Method of preserving platelets with apyrase and an antioxidant |
US5424471A (en) * | 1992-07-31 | 1995-06-13 | U.S. Bioscience, Inc. | Crystalline amifostine compositions and methods of the preparation and use of same |
CA2124690C (en) * | 1992-10-02 | 2007-09-11 | Thomas Osterberg | Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer |
IT1256622B (it) | 1992-12-04 | 1995-12-12 | Sclavo Spa | Processo per l'estrazione del complesso fattore viii-fattore von willebrand (fviii:c-fvw) da plasma umano totale. |
DE4242863A1 (de) | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF |
JPH08506498A (ja) | 1993-02-09 | 1996-07-16 | オクタファルマ・アクチエンゲセルシャフト | 非脂質被覆ウイルスの失活方法 |
SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
US5576291A (en) | 1993-09-13 | 1996-11-19 | Baxter International Inc. | Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency |
US5353835A (en) | 1993-09-23 | 1994-10-11 | Ingersoll-Rand Company | Air tank drain |
IT1268920B1 (it) | 1994-03-29 | 1997-03-13 | Syfal Srl | Macchina rotativa per la decorazione-smaltatura in particolare dipiastrelle ceramiche. |
IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
US5514781A (en) | 1994-04-11 | 1996-05-07 | Bayer Corporation | Use of azoles as virucidal agents in solutions of biologically active proteins |
US5955448A (en) | 1994-08-19 | 1999-09-21 | Quadrant Holdings Cambridge Limited | Method for stabilization of biological substances during drying and subsequent storage and compositions thereof |
FR2719479B1 (fr) * | 1994-05-04 | 1996-07-26 | Sanofi Elf | Formulation stable lyophilisée comprenant une protéine: kit de dosage. |
DK0762897T3 (da) | 1994-06-02 | 2003-07-21 | Elan Drug Delivery Ltd | Fremgangsmåde til forebyggelse af aggregering af proteiner/peptider ved rehydratisering eller optøning |
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
DE4431833C1 (de) | 1994-09-07 | 1995-05-18 | Blutspendedienst Der Drk Lande | Verfahren zur Herstellung eines AHF-Konzentrates |
GB2293100A (en) | 1994-09-15 | 1996-03-20 | Medeva Europ Ltd | Pharmaceutical compositions with deuterium oxide |
SE9403915D0 (sv) | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
SE503424C2 (sv) | 1994-11-14 | 1996-06-10 | Pharmacia Ab | Process för rening av rekombinant koagulationsfaktor VIII |
WO1996019918A1 (en) * | 1994-12-28 | 1996-07-04 | Biotime, Inc. | Plasma expanders and blood substitutes |
GB9501040D0 (en) * | 1995-01-19 | 1995-03-08 | Quadrant Holdings Cambridge | Dried composition |
SE9501189D0 (sv) * | 1995-03-31 | 1995-03-31 | Pharmacia Ab | Protein formulation |
US5679549A (en) | 1995-05-04 | 1997-10-21 | Bayer Corporation | Production of recombinant factor VIII in the presence of liposome-like substances of mixed composition |
JP3927248B2 (ja) * | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Hgf凍結乾燥製剤 |
KR0167677B1 (ko) * | 1995-08-31 | 1999-02-01 | 김광호 | 다중 비트 테스트를 위한 패턴 발생기를 가지는 메모리 테스트 시스템 |
SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
ES2099678B1 (es) | 1995-11-03 | 1998-02-16 | Grifols Grupo Sa | Procedimiento para la inactivacion de virus en proteinas. |
JP2000500137A (ja) | 1995-11-06 | 2000-01-11 | ニューヨーク・ブラッド・センター・インコーポレイテッド | フタロシアニン及び赤色光を用いた赤血球細胞のウイルス不活性化処理 |
US5659017A (en) | 1995-11-07 | 1997-08-19 | Alpha Therapeutic Corporation | Anion exchange process for the purification of Factor VIII |
US5925738A (en) | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
US5851800A (en) | 1996-05-14 | 1998-12-22 | Pharmacia & Upjohn Ab | Process for producing a protein |
US6632648B1 (en) | 1996-05-14 | 2003-10-14 | Elan Drug Delivery Limited | Methods of terminal sterilization of fibrinogen |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
JP5149470B2 (ja) * | 1999-02-22 | 2013-02-20 | バクスター・インターナショナル・インコーポレイテッド | 新規のアルブミンを含有していない第viii因子処方物 |
NZ516400A (en) | 1999-07-13 | 2004-02-27 | Biovitrum Ab | Stable factor VIII compositions |
US6440414B1 (en) * | 1999-10-01 | 2002-08-27 | Amgen Inc. | Pharmaceutical compositions of fibrinolytic agent |
EP2311437A1 (en) | 2003-12-19 | 2011-04-20 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
JO3324B1 (ar) | 2006-04-21 | 2019-03-13 | Amgen Inc | مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية |
PT2337580E (pt) | 2008-09-03 | 2012-05-28 | Octapharma Ag | Composições estabilizadas para o factor viii produzido de forma recombinante |
-
2000
- 2000-02-22 JP JP2000599425A patent/JP5149470B2/ja not_active Expired - Lifetime
- 2000-02-22 PL PL356453A patent/PL198123B1/pl unknown
- 2000-02-22 US US09/507,011 patent/US6586573B1/en not_active Expired - Lifetime
- 2000-02-22 PL PL382299A patent/PL203893B1/pl unknown
- 2000-02-22 AT AT00907322T patent/ATE365052T1/de active
- 2000-02-22 PL PL382300A patent/PL204701B1/pl unknown
- 2000-02-22 ES ES10075019.9T patent/ES2541470T3/es not_active Expired - Lifetime
- 2000-02-22 CA CA002634674A patent/CA2634674A1/en not_active Abandoned
- 2000-02-22 CA CA2362927A patent/CA2362927C/en not_active Expired - Lifetime
- 2000-02-22 CA CA002634663A patent/CA2634663C/en not_active Expired - Lifetime
- 2000-02-22 DK DK00907322T patent/DK1154796T3/da active
- 2000-02-22 DK DK06077229.0T patent/DK1820516T3/da active
- 2000-02-22 CN CN2009101711245A patent/CN101683522B/zh not_active Expired - Lifetime
- 2000-02-22 ES ES09075396T patent/ES2394755T3/es not_active Expired - Lifetime
- 2000-02-22 EP EP00907322A patent/EP1154796B1/en not_active Expired - Lifetime
- 2000-02-22 EP EP09075396A patent/EP2130554B1/en not_active Revoked
- 2000-02-22 EP EP15154020.0A patent/EP2921180B1/en not_active Expired - Lifetime
- 2000-02-22 AU AU28843/00A patent/AU777972B2/en not_active Expired
- 2000-02-22 CN CNB008063044A patent/CN100553678C/zh not_active Expired - Lifetime
- 2000-02-22 ES ES06077229T patent/ES2435141T3/es not_active Expired - Lifetime
- 2000-02-22 WO PCT/US2000/040068 patent/WO2000048635A1/en active Application Filing
- 2000-02-22 CZ CZ2008-828A patent/CZ307715B6/cs not_active IP Right Cessation
- 2000-02-22 CZ CZ20012996A patent/CZ300547B6/cs not_active IP Right Cessation
- 2000-02-22 PT PT09075396T patent/PT2130554E/pt unknown
- 2000-02-22 ES ES00907322T patent/ES2288843T3/es not_active Expired - Lifetime
- 2000-02-22 MX MXPA01008515A patent/MXPA01008515A/es active IP Right Grant
- 2000-02-22 RU RU2001125929/15A patent/RU2244556C2/ru active
- 2000-02-22 DK DK10075019.9T patent/DK2193809T3/en active
- 2000-02-22 CZ CZ2008-827A patent/CZ307322B6/cs not_active IP Right Cessation
- 2000-02-22 PT PT00907322T patent/PT1154796E/pt unknown
- 2000-02-22 CN CN200910171121A patent/CN101810854A/zh active Pending
- 2000-02-22 PL PL382288A patent/PL203177B1/pl unknown
- 2000-02-22 EP EP06077229.0A patent/EP1820516B1/en not_active Expired - Lifetime
- 2000-02-22 BR BRPI0008405-0B1A patent/BR0008405B1/pt not_active IP Right Cessation
- 2000-02-22 DK DK09075396.3T patent/DK2130554T3/da active
- 2000-02-22 EP EP10075019.9A patent/EP2193809B1/en not_active Expired - Lifetime
- 2000-02-22 DE DE60035260T patent/DE60035260T2/de not_active Expired - Lifetime
- 2000-02-22 PT PT100750199T patent/PT2193809E/pt unknown
- 2000-02-22 CA CA2634664A patent/CA2634664C/en not_active Expired - Lifetime
- 2000-02-22 PT PT60772290T patent/PT1820516E/pt unknown
-
2003
- 2003-07-01 US US10/610,723 patent/US7087723B2/en not_active Expired - Lifetime
-
2006
- 2006-05-15 US US11/434,634 patent/US7247707B2/en not_active Expired - Lifetime
-
2007
- 2007-06-18 US US11/764,770 patent/US8058226B2/en not_active Expired - Lifetime
- 2007-08-07 CY CY20071101050T patent/CY1108030T1/el unknown
- 2007-12-07 HK HK07113386.8A patent/HK1106705A1/xx not_active IP Right Cessation
- 2007-12-07 HK HK10106491.9A patent/HK1139862A1/xx not_active IP Right Cessation
- 2007-12-07 HK HK10100752.6A patent/HK1133583A1/ not_active IP Right Cessation
-
2008
- 2008-05-01 JP JP2008120035A patent/JP5006832B2/ja not_active Expired - Lifetime
- 2008-09-30 JP JP2008255510A patent/JP5140539B2/ja not_active Expired - Lifetime
-
2011
- 2011-09-30 US US13/250,789 patent/US8372800B2/en not_active Expired - Lifetime
-
2012
- 2012-01-20 JP JP2012009767A patent/JP5596064B2/ja not_active Expired - Lifetime
- 2012-12-04 CY CY20121101185T patent/CY1113969T1/el unknown
-
2013
- 2013-02-06 US US13/760,900 patent/US8765665B2/en not_active Expired - Lifetime
- 2013-11-01 JP JP2013227977A patent/JP6038003B2/ja not_active Expired - Lifetime
-
2014
- 2014-05-23 US US14/286,391 patent/US9352027B2/en not_active Expired - Fee Related
-
2015
- 2015-02-20 JP JP2015031316A patent/JP6155442B2/ja not_active Expired - Lifetime
- 2015-11-11 JP JP2015220875A patent/JP6253627B2/ja not_active Expired - Lifetime
-
2016
- 2016-02-18 HK HK16101857.2A patent/HK1213801A1/zh unknown
- 2016-05-04 US US15/146,835 patent/US9669076B2/en not_active Expired - Lifetime
-
2017
- 2017-04-27 JP JP2017088289A patent/JP2017125076A/ja not_active Withdrawn
-
2018
- 2018-07-02 JP JP2018125917A patent/JP2018172413A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2015091902A5 (ja) | ||
JP2016520075A5 (ja) | ||
JP2015231997A5 (ja) | ||
JP3898221B2 (ja) | トレハロースを含む乾燥血液因子組成物 | |
JP2014139229A5 (ja) | ||
JP2009540001A5 (ja) | ||
JP2013079270A5 (ja) | ||
JP2005538939A (ja) | 凍結乾燥フォームによる生物活性材料の保存 | |
JP2018506286A5 (ja) | ||
JP2014040441A5 (ja) | ||
RU2016150640A (ru) | Жидкая фармацевтическая композиция | |
JP2013543505A5 (ja) | ||
RU2011151286A (ru) | Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств | |
JP2013511522A (ja) | ダプトマイシン製剤 | |
RU2001125929A (ru) | Новые не содержащие альбумин составы фактора viii | |
WO2007016562A2 (en) | Formulations that inhibit protein aggregation | |
RU2011112787A (ru) | Новые защитные композиции для рекомбинантного фактора viii | |
JP2012136518A5 (ja) | ||
JP2020506691A5 (ja) | ||
JP2019512012A5 (ja) | ||
JP2015535243A5 (ja) | ||
JP2013544288A5 (ja) | ||
JP2017516848A5 (ja) | ||
EA201892446A1 (ru) | Фармацевтическая композиция | |
HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela |